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Recent identification of synthetic lethal interactions involving several proteins of the SWI/SNF complex discussed in
this Research Highlight has opened the possibility of new cancer therapeutic approaches.
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BRG1, SMARCA4, BRM, SMARCA2, MAX, MYCResearch over the two last decades has shown that epigen-
etic deregulation is a common feature in carcinogenesis.
With the latest advances in cancer genome sequencing,
the occurrence of inactivating mutations in SWI/SNF
chromatin-remodeling genes in several tumor types has
attracted a great deal of interest. The SWI/SNF complex
alters the interactions between DNA and histones using
the energy of ATP hydrolysis, modifying the availability of
DNA’s information to the cellular machinery. In this way,
the SWI/SNF complex can modify gene expression, such
as by controlling the accessibility of DNA to transcription
factors, thereby controlling transcription as a whole.
Various studies have determined that genes encoding
subunits of the SWI/SNF chromatin-remodeling com-
plex are mutated in cancer about 20% of the time. Initial
insights into the role of the SWI/SNF complex in
tumorigenesis arose from the identification of the core
subunit SMARCB1/SNF5 in malignant rhabdoid tumors,
following demonstration of its tumor suppressor function
in cell lines and animal models. Subsequently, muta-
tions and/or loss of expression of the catalytic subunit
SMARCA4 have been reported predominantly in non-
small cell lung cancer (NSCLC), as well as other can-
cers. Furthermore, mutations in the accessory core
subunit ARID1A have been reported in ovarian clear
cell and endometrial carcinomas, among other cancers,
and PBRM mutations have been reported in clear renal
cell carcinomas.* Correspondence: pedromedina@ugr.es
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article, unless otherwise stated.Synthetic lethality strategies dependent on the
mutational status of SWI/SNF complex proteins
Recent understanding of the role and importance of the
SWI/SNF complex in tumor development has opened
the door to new potential therapeutic strategies based
on the concept of synthetic lethality [1].
Synthetic lethality is defined as a type of genetic inter-
action where the co-occurrence of two genetic events results
in organismal or cellular death. The term also can be applied
to cancer biology. During their transformation, cancer cells
acquire genetic and epigenetic variations that distinguish
them from their wild-type counterparts. Consequently, can-
cer cells have been reprogrammed, exposing new genetic
and epigenetic vulnerabilities. Synthetic lethal interaction
partners of cancer-associated molecular changes should
therefore offer therapeutic opportunities. In recent years,
synthetic lethality has attracted attention in the field of
oncology, as it provides a new angle for therapy and may
explain the sensitivity of cancer cells to certain drugs.
In this Research Highlight, we will discuss some of the
potential therapeutic strategies that can be developed by
targeting the SWI/SNF complex using the concept of
synthetic lethality [2-5] (Figure 1).Synthetic lethality in tumors with SMARCA4
mutations after inhibition of SMARCA2
The SWI/SNF complex contains one of the two mutually ex-
clusive DNA-dependent ATPases, SMARCA4 (also known
as BRG1), and SMARCA2 (also known as BRM). Although
SMARCA4 and SMARCA2 display high homology and pre-
sumably have overlapping functions, other observations sug-
gest that they have different roles in cancer. For instance,
tumor sequencing has unveiled some of these functional dif-
ferences: SMARCA2 inactivation by mutation is infrequentd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Recently proposed therapeutic models that exploit synthetic lethality strategies involving SWI/SNF proteins. The red inhibition
line indicates the therapeutic strategy in the specific tumor cells assayed in the reports referenced in the figure. Proteins with dotted lines
indicate expression inactivation. NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, OCCAs: ovarian clear cell adenocarcinomas.
Schiaffino-Ortega et al. Journal of Hematology & Oncology 2014, 7:81 Page 2 of 3
http://www.jhoonline.org/content/7/1/81in tumor development; however, SMARCA4 has been found
mutated in primary tumors and cancer cell lines. The first
somatic mutation of SMARCA4 was described in an NSCLC
tumor [6], and expression inactivation by mutation was also
frequently found in NSCLC cell lines [7]. Using these
findings, three research groups sought to test whether
depletion of SMARCA2 might be synthetically lethal in
SMARCA4-mutant lung tumors [2,4,5].
In a pioneer study, Oike et al. screened siRNA against
SMARCA2 in a panel of SMARCA4 mutant NSCLC cell
lines and found that the inhibition of SMARCA2 signifi-
cantly decreased cell viability compared with control
siRNA, whereas SMARCA4 wild-type cells were unaffected.
They extended these results to a xenograft mouse model of
NSCLC [5]. Independently, another group studied the same
relationship and found that SMARCA4 inactivation leads to
greater incorporation of the nonessential SMARCA2 sub-
unit into the SWI/SNF complex [2]. Wilson and colleagues
observed that this residual SWI/SNF complex exists in
SMARCA4-mutant cell lines and plays essential roles in
cellular proliferation. Additionally, using data from loss-
of-function screening of 165 cancer cell lines, the authors
identified SMARCA2 as the top essential gene, even more
than TP53, in SMARCA4 mutant cancer cell lines [2].
Hoffman et al. also identified SMARCA2 as being es-
sential for the growth of tumor cells that harbor loss of
function mutations in SMARCA4 [4]. The researchers
depleted SMARCA2 in SMARCA4-deficient cancer cell
lines and xenograft models and observed cycle arrest, in-
duction of senescence, and increased level of the repres-
sive marker H3K9me3. The authors proposed that such
synthetic lethality might be explained by paralog insuffi-
ciency, in which loss of one family member unveils crit-
ical dependence on paralogous subunits [4].
Synthetic lethality in tumors with MAX mutations
after inhibition of SMARCA4
Recently, Romero and colleagues found another putative
synthetic lethality that also involves SMARCA4 and thatcould be exploited as a putative therapy in small cell
lung cancer (SCLC) [3]. Studying the inactivation of MYC-
associated factor X (MAX) gene in SCLC, they found that
about 6% of the tumors have homozygous and tumor-
specific mutations in MAX. Interestingly, the authors
observed that the alterations in MAX and amplification
of the MYC genes were mutually exclusive, and none of
the MAX-mutant cells carried concomitant mutations of
SMARCA4. The researchers observed that SMARCA4 was
able to regulate MAX expression by binding specifically to
its promoter, and that depletion of SMARCA4 strongly
hinders cell growth, specifically in MAX-deficient cells,
indicating a synthetic lethal interaction that could be
therapeutically exploited [3].
Synthetic lethality in tumors with ARID1A
mutations after inhibition of ARID1B
Recent studies have revealed that another member of
the SWI/SNF complex, ARID1A, which encodes AT-rich
interactive domain 1A, is frequently mutated across a
variety of human cancers (including ovarian, breast, and
lung, among others) and also has bona fide tumor sup-
pressor properties. Using a broad screening approach,
Helming et al. identified ARID1B, an ARID1A homolog
whose gene product is mutually exclusive with ARID1A
in SWI/SNF complexes [8], as the preferentially required
gene for the survival of ARID1A-mutant ovarian cancer
cell lines. The authors showed that loss of ARID1B in
ARID1A-deficient backgrounds destabilizes SWI/SNF and
impairs proliferation in both cancer cells and primary
cells, thus acting as a synthetic lethal and opening new
therapeutic opportunities.
Small-molecule drugs to therapeutically exploit
the SWI/SNF complex
Epigenetic proteins have been intently pursued as targets
for cancer therapy. However, it was thought that SWI/
SNF complex proteins were not good targets for cancer
therapy due to the tumor suppressor activities of the
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scribing synthetic lethality interactions between mem-
bers of the SWI/SNF complex with putative therapeutic
applications may have changed this point of view.
A new therapeutic approach includes the use of in-
hibitors that specifically target bromodomains. The proof
of concept of these small cell-permeable inhibitors came
from a report where the inhibitor I-BET151 was able to
bind specifically to the bromodomains of BRD3/4 and be
therapeutically active in MLL-fusion leukemia [9]. The
bromodomain is a highly conserved motif of 110 amino
acids that is bundled into four anti-parallel α-helices that
are able to bind to acetylated lysines in the histones of nu-
cleosomal chromatin. These domains are therefore able to
read information of the histone code. Importantly, the
SWI/SNF complex has several proteins with these drug-
gable bromodomains, including SMARCA4, SMARCA2,
BRD9, and PBRM1. In this way, for example, the specific
inhibition of SMARCA2 could have a therapeutic benefit in
SMARCA4 mutant tumors. In the same way, the inhibition
of SMARCA4 could have therapeutic benefits in MAX mu-
tant tumors.
Additionally, these drugs may be exploited in other
genetic contexts where the SWI/SNF activities are ne-
cessary to maintain the tumor phenotype. For example,
recent reports have observed that while in most of the
tumor types studied, SMARCA4 is known to have a
tumor suppressive function, leukemia cells instead rely
on SMARCA4 to support their oncogenic transcriptional
program [10,11].Conclusions
The recent identification of synthetic lethal interactions
involving several subunits of the SWI/SNF complex has
opened the possibility of new therapeutic approaches
that can be exploited using a new generation of epigen-
etic inhibitors. A recent report suggested that the incipi-
ent microRNA-based technology could be also in the
arsenal to target SWI/SNF proteins [12]. As the field of
molecular therapeutics on epigenetic proteins rapidly ex-
pands, several features of protein function will need to
be considered, including possible off-target inhibition or
uncontrolled transcriptional derepression of genes, al-
tered hematopoiesis, and immunosuppression or reacti-
vation of latent viruses. Despite these possible pitfalls,
the harnessing of SWI/SNF for clinical applications holds
great promise, and oncologists are increasingly interested
in this therapeutic potential.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors read and approved the final manuscript.Acknowledgements
P.P.M. laboratory is funded by Ministry of Economy of Spain (SAF-2012- 37252),
Junta de Andalucía (CICE-FEDER-BIO-1655, PeS-FEDER-PI-0903-2012), EU-MarieCurie
(CIG-321926), CEI-BIOTIC (20 F12.6), Deutsche Leukämie-Stiftung and BBVA
Foundation. P.P.M is a Ramon y Cajal Researcher (RYC-2011-07766). S S-O
has a postdoctoral fellowship of Junta de Andalucía (CTS 03210) and the
support of the CEI-BIOTIC (2014-MPBS33).
Received: 3 September 2014 Accepted: 18 October 2014
References
1. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH: Integrating
genetic approaches into the discovery of anticancer drugs. Science 1997,
278:1064–1068.
2. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC,
Roberts CW: Residual complexes containing SMARCA2 (BRM) underlie the
oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 2014,
34:1136–1144.
3. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C,
Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M:
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs
and is synthetic lethal with BRG1. Cancer Discov 2014, 4:292–303.
4. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L,
Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, Haas K,
Jaskelioff M, Wilson BG, Meyer MJ, Saenz-Vash V, Zhai H, Myer VE, Porter JA,
Keen N, McLaughlin ME, Mickanin C, Roberts CW, Stegmeier F, Jagani Z:
Functional epigenetics approach identifies BRM/SMARCA2 as a critical
synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A
2014, 111:3128–3133.
5. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y,
Isomura H, Komachi M, Furuta K, Watanabe S, Nakano T, Yokota J, Kohno T: A
synthetic lethality-based strategy to treat cancers harboring a genetic
deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013,
73:5508–5518.
6. Medina PP, Carretero J, Fraga MF, Esteller M, Sidransky D, Sanchez-Cespedes M:
Genetic and epigenetic screening for gene alterations of the chromatin-
remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes
Cancer 2004, 41:170–177.
7. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J,
Sanchez-Cespedes M: Frequent BRG1/SMARCA4-inactivating mutations
in human lung cancer cell lines. Hum Mutat 2008, 29:617–622.
8. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y,
Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC,
Roberts CW: ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Nat Med 2014, 20:251–254.
9. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI,
Robson SC, Chung CW, Hopf C, Savitski MM, Huthmacher C, Gudgin E,
Lugo D, Beinke S, Chapman TD, Roberts EJ, Soden PE, Auger KR, Mirguet O,
Doehner K, Delwel R, Burnett AK, Jeffrey P, Drewes G, Lee K, Huntly BJ,
Kouzarides T: Inhibition of BET recruitment to chromatin as an effective
treatment for MLL-fusion leukaemia. Nature 2011, 478:529–533.
10. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL,
Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S,
Zhu Z, Kendall J, Muhar M, Haslinger C, Yu M, Roeder RG, Wigler MH,
Blobel GA, Zuber J, Spector DL, Young RA, Vakoc CR: Role of SWI/SNF in
acute leukemia maintenance and enhancer-mediated Myc regulation.
Genes Dev 2013, 27:2648–2662.
11. Buscarlet M, Krasteva V, Ho L, Simon C, Hebert J, Wilhelm B, Crabtree GR,
Sauvageau G, Thibault P, Lessard JA: Essential role of BRG, the ATPase
subunit of BAF chromatin remodeling complexes, in leukemia
maintenance. Blood 2014, 123:1720–1728.
12. Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C,
Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M., Reyes-Zurita F, Lupiáñez JA,
Sánchez-Cespedes M., Slack FJ Medina PP: Expression inactivation of
SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics
2014, doi:10.1093/hmg/ddu554
doi:10.1186/s13045-014-0081-5
Cite this article as: Schiaffino-Ortega et al.: SWI/SNF proteins as targets
in cancer therapy. Journal of Hematology & Oncology 2014 7:81.
